Filing summary
Entity and period mismatch: The supplied filing is Venaxis, Inc.’s Form 10-K for the fiscal year ended December 31, 2015, filed March 23, 2016. It is not a filing for Riot Platforms, Inc. The filing is annual, although it includes unaudited quarterly data for 2015.
Business context and reporting period
Venaxis was a small diagnostic-development company focused primarily on its APPY 1 blood test for assessing appendicitis risk. The FDA did not clear the test in January 2015, and management concluded it lacked the resources to pursue the additional prospective study the FDA indicated would be required. The company was exploring strategic alternatives, seeking to monetize its appendicitis assets, and receiving license revenue related to animal-health assets licensed to Ceva.
Key financial metrics
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Total revenue | $198,086 | $262,654 |
| Net loss | $8.76 million | $10.44 million |
| Basic and diluted loss per share | $0.28 | $0.36 |
| Net cash used in operating activities | $6.87 million | $9.20 million |
| Current assets | $16.41 million | $24.90 million |
| Working capital | $14.62 million | Not stated here |
| Total assets | $20.86 million | $28.72 million |
| Total liabilities | $4.79 million | $5.04 million |
- Product sales were $101,000, down from $167,000; animal-health license revenue was $97,000, versus $96,000. Product gross margin was 70%, compared with 57% in 2014.
- At year-end, cash and cash equivalents were $2.01 million, short-term investments $14.15 million, and long-term investments $972,000. Management reported cash and liquid investments of approximately $16.16 million.
- Year-end notes and other obligations totaled $2.14 million, including $2.00 million in mortgage notes. The mortgage and other long-term debt were paid off from the February 2016 property sale proceeds.
- Investing activities provided $5.79 million in 2015, largely reflecting net sales of marketable securities. Financing activities used $454,000, primarily for debt repayments. No equity offering occurred in 2015.
Material changes versus the prior comparable period
- Revenue decreased about 25% year over year, as lower APPY 1 product sales more than offset a small increase in license revenue.
- Net loss narrowed by about 16%, and operating cash use improved by about 25%. R&D expense fell 46% to $2.16 million, following completion of clinical work and reduced APPY 2 development activity. SG&A rose 3% to $6.76 million, including $1.02 million of strategic-evaluation costs and higher legal costs.
- Cash and investments declined from approximately $24.54 million at year-end 2014 to $17.13 million at year-end 2015, including long-term investments in the latter figure. The company also reported a $105.58 million accumulated deficit.
- Shares outstanding at year-end were 30.99 million, compared with a weighted-average 28.63 million in 2014; the increase principally reflects 2014 equity issuance and exercises.
Outlook, risks, contingencies, and unusual items
- Management expected continued operating losses and estimated available working capital would fund needs into early 2017. This is an estimate, not a guarantee; the filing notes reliance on equity financing and possible need for additional capital.
- The January 2016 Strand transaction was terminated by mutual agreement on March 11, 2016. Venaxis reported approximately $1.25 million of costs associated with the terminated transaction and began evaluating other strategic alternatives. No successor transaction was assured.
- On February 25, 2016, the company sold its headquarters for $4.053 million, receiving approximately $1.7 million net after expenses and mortgage payoffs, and entered short-term leasebacks. This occurred after the reporting date.
- APPY 1 had CE marking in Europe but no FDA clearance. EU sales were below break-even; the company began winding down those commercial activities and terminating distributor arrangements in early 2016. If no buyer or partner is found, approximately $508,000 of capitalized appendicitis patent costs could be impaired.
- NASDAQ initiated delisting proceedings because the share price failed the $1.00 minimum bid requirement. The company appealed, with a hearing scheduled for April 21, 2016, and sought shareholder authorization for a reverse split of between one-for-four and one-for-ten. The outcome was uncertain.
- Other notable items: $188,000 of patent impairment charges in 2015; the Bealer contract dispute settled in December 2015 for an undisclosed amount without admission of liability; a securities class action was voluntarily dismissed without prejudice in August 2015. The company reported no other legal proceedings believed likely to have a material adverse effect.
- The audited financial statements received an unqualified opinion. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2015. No income tax benefit was recorded; approximately $96 million of net operating loss carryforwards were subject to a full valuation allowance.
Most important facts for investors to verify
- Confirm the issuer: this filing is for Venaxis, Inc., not Riot Platforms, Inc., and the reporting period is FY 2015.
- Review subsequent filings for the outcome of the NASDAQ appeal and reverse-split proposal, and the company’s eventual listing status.
- Check post-year-end cash, liquidity, operating burn, and any financing or strategic transaction; the early-2017 runway estimate depended on management’s assumptions.
- Determine whether appendicitis assets were sold, licensed, impaired, or further developed, and whether the EU wind-down generated additional costs.
- Assess the status and collectability of potential Ceva milestones and royalties; they depend on development, regulatory, and commercial success.